Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company dedicated to identifying, developing, and commercializing novel pharmaceutical products for skin diseases and conditions with significant unmet needs. The company is headquartered in West Chester, Pennsylvania, and was founded in 2013.

Verrica's lead commercial product is YCANTH (VP-102), a cantharidin-based topical solution, which is the first and only healthcare professional-administered treatment approved by the FDA for molluscum contagiosum in adults and pediatric patients aged two years and older. The company's pipeline also includes YCANTH (VP-102) in development for common warts, and VP-315 (ruxotemitide), an oncolytic peptide for non-melanoma skin cancers, including basal cell carcinoma.

Jayson Rieger serves as the President and CEO of Verrica Pharmaceuticals. Recent notable developments include the acceptance of a late-breaking abstract in April 2026 highlighting the potential abscopal effect of VP-315 for basal cell carcinoma, and the reporting of strong Q4 and full-year 2025 financial results in March 2026, which showed growth in YCANTH net revenue. The company also launched YCANTH in Japan in February 2026 through a partnership with Torii Pharmaceutical and initiated a global Phase 3 program for YCANTH in common warts in late 2025.